Analyst Briefing Submitted
ddpharmatech.com

Founded Year

2014

Stage

Series C | Alive

Total Raised

$206.61M

Last Raised

$51M | 7 mos ago

About D&D Pharmatech

D&D Pharmatech is a healthcare holding company that develops therapeutics for dementia, Alzheimer's disease, and Parkinson's disease.

D&D Pharmatech Headquarter Location

2nd Floor 225-18, Pangyoyeok-ro, Bundang-gu

Seongnam, 13494,

South Korea

037-8019-7771

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

D&D Pharmatech's Products & Differentiation

See D&D Pharmatech's products and how their products differentiate from alternatives and competitors

  • NLY01

    1) Potential first-in-class microglia targeting disease modifying therapy for treatment of both Parkinson's and Alzheimer’s disease 2) Once-weekly, peptide-based GLP-1 receptor agonist 3) Binds to upregulated GLP-1R in activated microglia (by a-Syn fibrils in PD and β-amyloid fibrils in AD patients) and effectively shuts down microglial activation 4) In turn, prevents formation of neurotoxic reactive A1 astrocytes and subsequent neuronal death thereby halts or slows down disease progression 5) Phase 2 study in patients with early-stage Parkinson's disease - Ongoing (n=240) 6) Phase 2b study in patients with mild cognitive impairment due to Alzheimer's disease - US IND cleared (n=518)

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

Expert Collections containing D&D Pharmatech

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

D&D Pharmatech is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

D&D Pharmatech Patents

D&D Pharmatech has filed 4 patents.

The 3 most popular patent topics include:

  • Diabetes
  • Peptide hormones
  • Clusters of differentiation
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/11/2015

4/12/2022

Clusters of differentiation, Autoimmune diseases, Immunology, Immune system, Monoclonal antibodies

Grant

Application Date

3/11/2015

Grant Date

4/12/2022

Title

Related Topics

Clusters of differentiation, Autoimmune diseases, Immunology, Immune system, Monoclonal antibodies

Status

Grant

Latest D&D Pharmatech News

Korea-based D&D under Johns Hopkins team in spotlight for novel dementia therapy - 매일경제 영문뉴스 펄스(Pulse)

Mar 3, 2022

D&D Pharmatech, a clinical-stage global biotech company, features a strong research emphasis, with focus on neurodegenerative brain disorders led by Johns Hopkins University School of Medicine neuroscientists, including Ted M. Dawson, MD, PhD, who is a globally recognized authority in this domain. The company’s founder Lee Seulki, PhD, 45, also working at the university as a radiology professor, is a promising medical scientist who is the youngest `Highly Cited Researcher` named by Clarivate Analytics in 2017.

D&D Pharmatech Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

D&D Pharmatech Rank

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.